Monthly
US$200
Billed every month
帕拉米韦氯化钠注射液
Companies, stages and changes, with each record available on this page.
Last 90 days: Marketing application approved: 1 applicationAccepted: 2 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders8View records ↓
Under-review filings17View records ↓
This year’s generic filers4View records ↓
NHSA approval numbers16View records ↓
API companies with A status0View records ↓
Chemical-drug catalogue
Loaded records: 8 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 8 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 博智安健（河北）药业有限公司 | 山东华鲁制药有限公司 | 国药准字H20265274 | 2026/07/21 | 100ml︰帕拉米韦（按C15H28N4O4计）0.15g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东大翔制药有限公司 | 广东大翔制药有限公司 | 国药准字H20264777 | 2026/06/10 | 100ml：帕拉米韦（按C15H28N4O4计）0.15g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏长江药业有限公司 | 江苏长江药业有限公司 | 国药准字H20264458 | 2026/05/19 | 100ml:帕拉米韦（按C15H28N4O4计）0.15g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏长江药业有限公司 | 江苏长江药业有限公司 | 国药准字H20264459 | 2026/05/19 | 100ml:帕拉米韦（按C15H28N4O4计）0.3g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄四药有限公司 | 石家庄四药有限公司 | 国药准字H20264443 | 2026/05/19 | 100ml︰帕拉米韦（按C15H28N4O4计）0.3g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄四药有限公司 | 石家庄四药有限公司 | 国药准字H20264442 | 2026/05/19 | 100ml︰帕拉米韦（按C15H28N4O4计）0.15g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南九维生物医药有限公司 | 湖南金健药业有限责任公司 | 国药准字H20264215 | 2026/04/29 | 100ml︰帕拉米韦（按C15H28N4O4计）0.3g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南九维生物医药有限公司 | 湖南金健药业有限责任公司 | 国药准字H20264216 | 2026/04/29 | 100ml︰帕拉米韦（按C15H28N4O4计）0.15g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京恒道医药科技股份有限公司 | 武汉福星生物药业有限公司 | 国药准字H20263763 | 2026/03/31 | 100ml︰帕拉米韦（按C15H28N4O4计）0.15g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 仁合益康集团有限公司 | 河北仁合益康药业有限公司 | 国药准字H20255760 | 2025/10/21 | 100ml 帕拉米韦（按C15H28N4O4计）0.15g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 仁合益康集团有限公司 | 河北仁合益康药业有限公司 | 国药准字H20255761 | 2025/10/21 | 100ml 帕拉米韦（按C15H28N4O4计）0.3g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东齐都药业有限公司 | 山东齐都药业有限公司 | 国药准字H20255050 | 2025/07/29 | 100ml︰帕拉米韦（按C15H28N4O4计）0.3g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东齐都药业有限公司 | 山东齐都药业有限公司 | 国药准字H20255049 | 2025/07/29 | 100ml:帕拉米韦（按C15H28N4O4计）0.15g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东大翔制药有限公司 | 广东大翔制药有限公司 | 国药准字H20264778 | 2026/06/10 | 100ml：帕拉米韦（按C15H28N4O4计）0.3g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 16 distinct approval numbers and 9 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 广州南新制药有限公司 | 国药准字H20170004 | 100ml:帕拉米韦(按C15H28N4O4计)0.15g与氯化钠0.9g | Category B (乙) | XJ05AHP119B002010100407 | NHSA |
| 江苏长江药业有限公司 | 国药准字H20264458 | 100ml:帕拉米韦(按C₁₅H₂₈N₄O₄计)0.15g与氯化钠0.9g | Category B (乙) | XJ05AHP119B002010101426 | NHSA |
| 石家庄四药有限公司 | 国药准字H20264443 | 100ml:帕拉米韦(按C₁₅H₂₈N₄O₄计)0.3g与氯化钠0.9g | Category B (乙) | XJ05AHP119B002010102763 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20255049 | 100ml︰帕拉米韦(按C₁₅H₂₈N₄O₄计)0.15g与氯化钠0.9g | Category B (乙) | XJ05AHP119B002010104145 | NHSA |
| 湖南九维生物医药有限公司 | 国药准字H20264215 | 100ml 帕拉米韦(按C₁₅H₂₈N₄O₄ 计)0.3g与氯化钠0.9g | Category B (乙) | XJ05AHP119B002010104936 | NHSA |
| 广东大翔制药有限公司 | 国药准字H20264778 | 100ml:帕拉米韦(按C₁₅H₂₈N₄O₄计)0.3g与氯化钠0.9g | Category B (乙) | XJ05AHP119B002010109938 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20255760 | 100ml︰帕拉米韦(按C₁₅H₂₈N₄O₄计)0.15g与氯化钠0.9g | Category B (乙) | XJ05AHP119B002010183033 | NHSA |
| 南京恒道医药科技股份有限公司 | 国药准字H20263763 | 100ml : 帕拉米韦(按C₁₅H₂₈N₄O₄ 计)0.15g与氯化钠0.9g | Category B (乙) | XJ05AHP119B002010183035 | NHSA |
| 博智安健(河北)药业有限公司 | 国药准字H20265274 | 100ml:帕拉米韦(按C₁₅H₂₈N₄O₄ 计)0.15g与氯化钠0.9g | Category B (乙) | XJ05AHP119B002010185749 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20255760 | 100ml︰帕拉米韦(按C₁₅H₂₈N₄O₄计)0.15g与氯化钠0.9g | Category B (乙) | XJ05AHP119B002010283033 | NHSA |
| 广州南新制药有限公司 | 国药准字H20130029 | 100ml:帕拉米韦(按C15H28N4O4计)0.3g与氯化钠0.9g | Category B (乙) | XJ05AHP119B002020100407 | NHSA |
| 江苏长江药业有限公司 | 国药准字H20264459 | 100ml:帕拉米韦(按C₁₅H₂₈N₄O₄计)0.3g与氯化钠0.9g | Category B (乙) | XJ05AHP119B002020101426 | NHSA |
| 石家庄四药有限公司 | 国药准字H20264442 | 100ml:帕拉米韦(按C₁₅H₂₈N₄O₄计)0.15g与氯化钠0.9g | Category B (乙) | XJ05AHP119B002020102763 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20255050 | 100ml︰帕拉米韦(按C₁₅H₂₈N₄O₄计)0.3g与氯化钠0.9g | Category B (乙) | XJ05AHP119B002020104145 | NHSA |
| 湖南九维生物医药有限公司 | 国药准字H20264216 | 100ml︰帕拉米韦(按C₁₅H₂₈N₄O₄计)0.15g与氯化钠0.9g | Category B (乙) | XJ05AHP119B002020104936 | NHSA |
| 广东大翔制药有限公司 | 国药准字H20264777 | 100ml:帕拉米韦(按C₁₅H₂₈N₄O₄计)0.15g与氯化钠0.9g | Category B (乙) | XJ05AHP119B002020109938 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20255761 | 100ml︰帕拉米韦(按C₁₅H₂₈N₄O₄计)0.3g与氯化钠0.9g | Category B (乙) | XJ05AHP119B002020183033 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20255761 | 100ml︰帕拉米韦(按C₁₅H₂₈N₄O₄计)0.3g与氯化钠0.9g | Category B (乙) | XJ05AHP119B002020283033 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 17 filings and 9 distinct first applicants.
Generic 17
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 苏州第壹制药有限公司;浙江国镜药业有限公司 | CYHS2600435 | Generic | 2026/02/10 | Not stated by source | CDE |
| 苏州第壹制药有限公司;浙江国镜药业有限公司 | CYHS2600434 | Generic | 2026/02/10 | Not stated by source | CDE |
| 江苏亚尧生物科技有限公司;安徽丰原药业股份有限公司 | CYHS2502364 | Generic | 2025/07/04 | Not stated by source | CDE |
| 江苏亚尧生物科技有限公司;安徽丰原药业股份有限公司 | CYHS2502363 | Generic | 2025/07/04 | Not stated by source | CDE |
| 信合援生制药股份有限公司 | CYHS2601388 | Generic | 2026/06/11 | Not stated by source | CDE |
| 信合援生制药股份有限公司 | CYHS2601387 | Generic | 2026/06/11 | Not stated by source | CDE |
| 四川健林药业有限责任公司;扬子江药业集团四川海蓉药业有限公司 | CYHS2600368 | Generic | 2026/02/04 | Not stated by source | CDE |
| 辰欣药业股份有限公司 | CYHS2504220 | Generic | 2025/12/09 | Not stated by source | CDE |
| 辰欣药业股份有限公司 | CYHS2504219 | Generic | 2025/12/09 | Not stated by source | CDE |
| 浙江康吉尔药业有限公司 | CYHS2503382 | Generic | 2025/09/12 | Not stated by source | CDE |
| 浙江康吉尔药业有限公司 | CYHS2503381 | Generic | 2025/09/12 | Not stated by source | CDE |
| 珠海同源药业有限公司 | CYHS2503167 | Generic | 2025/08/29 | Not stated by source | CDE |
| 珠海同源药业有限公司 | CYHS2503166 | Generic | 2025/08/29 | Not stated by source | CDE |
| 哈尔滨三联药业股份有限公司 | CYHS2503015 | Generic | 2025/08/16 | Not stated by source | CDE |
| 哈尔滨三联药业股份有限公司 | CYHS2503014 | Generic | 2025/08/16 | Not stated by source | CDE |
| 河北天成药业股份有限公司 | CYHS2602675 | Generic | 2026/11/02 | Not stated by source | CDE |
| 河北天成药业股份有限公司 | CYHS2602674 | Generic | 2026/11/02 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 7 filings and 4 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 苏州第壹制药有限公司;浙江国镜药业有限公司 | CYHS2600435 | Generic | 2026/02/10 | Not stated by source | CDE |
| 苏州第壹制药有限公司;浙江国镜药业有限公司 | CYHS2600434 | Generic | 2026/02/10 | Not stated by source | CDE |
| 信合援生制药股份有限公司 | CYHS2601388 | Generic | 2026/06/11 | Not stated by source | CDE |
| 信合援生制药股份有限公司 | CYHS2601387 | Generic | 2026/06/11 | Not stated by source | CDE |
| 四川健林药业有限责任公司;扬子江药业集团四川海蓉药业有限公司 | CYHS2600368 | Generic | 2026/02/04 | Not stated by source | CDE |
| 河北天成药业股份有限公司 | CYHS2602675 | Generic | 2026/11/02 | Not stated by source | CDE |
| 河北天成药业股份有限公司 | CYHS2602674 | Generic | 2026/11/02 | Not stated by source | CDE |
API registrations
Non-component matches: 0 companies with A status and 0 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/03Marketing application approved
山西诺成制药有限公司
CYHS2501707 · 国药准字H20266470
Fact date: 2026/11/03 · Publication date: 2026/11/05 · Site observation date: 2026/11/06
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 72 ↗ -
2026/11/02Accepted
-
2026/11/02Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to this drug
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy